Welcome to our dedicated page for Dexcom SEC filings (Ticker: DXCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The DexCom, Inc. (DXCM) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports on Form 8-K, annual reports on Form 10-K, and quarterly reports on Form 10-Q when filed. Dexcom is listed on the Nasdaq Stock Market under the symbol DXCM, and its SEC filings offer detailed information on financial performance, governance, and material events related to its glucose biosensing and continuous glucose monitoring (CGM) business.
Recent Form 8-K filings illustrate how Dexcom uses SEC reports to communicate key developments. For example, the company has filed 8-Ks to furnish quarterly financial results, including revenue by geography and product component, and to describe leadership transitions such as the appointment of Jacob S. Leach as President and Chief Executive Officer and the appointment of Dr. Euan Ashley to the Board of Directors. These filings also document changes in board size, committee assignments, and executive roles.
Dexcom’s periodic reports, including 10-K and 10-Q filings when available, typically contain audited financial statements, discussions of sensor and hardware revenue, descriptions of its CGM and biosensing operations, and risk factor disclosures. Investors can also review sections on research and development spending, capital structure, and non-GAAP performance metrics that the company discusses alongside GAAP results in its earnings-related 8-Ks.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight the most important points from lengthy documents, helping readers quickly understand revenue trends, margin commentary, governance updates, and other material items. Users can also monitor items related to director and executive appointments or departures, and other reportable events under Form 8-K. This page is a central resource for analyzing Dexcom’s regulatory history and for tracking how financial and governance information evolves over time.
Osterloh Albert Frederick IV reported acquisition or exercise transactions in this Form 4 filing.
DexCom, Inc. director Albert Frederick Osterloh IV reported receiving a grant of 7,061 restricted stock units of common stock. The award was made at a stated price of $0.00 per share and represents a contingent right to receive 7,061 DexCom common shares.
The restricted stock units vest in three equal annual installments from the grant date, meaning one‑third of the units is scheduled to vest each year over three years, subject to the grant’s terms.
Dexcom Inc. director Albert Frederick Osterloh IV has filed an initial Form 3, which is the baseline statement of his ownership in the company’s securities as an insider. The filing reports no transactions, meaning there are no recent insider share purchases, sales, or other dealings disclosed in this document.
Dexcom expanded its Board of Directors to twelve members and appointed Rick Osterloh, a senior Google executive, as an independent director effective February 26, 2026, with his term running until the 2026 annual meeting of stockholders.
Osterloh will serve on the Compensation Committee and Technology Committee. Upon appointment, he received restricted stock units with a fair value of $500,000, vesting annually over three years, and he is eligible for a pro-rated 2026 annual RSU award valued at $101,027. All non-employee director equity vests in full upon a change in control of Dexcom.
DexCom director Bridgette P. Heller reported an open-market sale of 1,012 shares of Common Stock on February 12, 2026 at $68.01 per share under a pre-arranged Rule 10b5-1 trading plan adopted on August 14, 2025. Following this transaction, she beneficially owns 26,019 shares, including 5,046 unvested restricted stock units granted on May 8, 2025 that will vest on the earlier of the one-year anniversary of the grant date or DexCom, Inc.'s 2026 Annual Meeting of Stockholders.
DexCom, Inc. files its annual report describing its continuous glucose monitoring business, led by the G7 and new G7 15 Day systems, Dexcom ONE+ and the Stelo over-the-counter biosensor.
The filing outlines intense competition, extensive global regulatory and privacy obligations, an FDA warning letter on manufacturing and quality systems, and evolving U.S. fraud-and-abuse rules. It also highlights Medicare and commercial coverage, noting that a new competitive bidding program and rental model are expected to reduce Medicare reimbursement for CGM systems starting in 2028.
Dexcom reported strong fourth quarter and full-year 2025 results, with revenue reaching $1.260 billion in Q4, up 13% year over year, and $4.662 billion for 2025, up 16%.
Profitability improved meaningfully. Q4 GAAP operating income rose to $323.0 million (25.6% margin), while full-year GAAP operating income reached $911.8 million (19.6% margin). GAAP net income for 2025 increased to $836.3 million, or $2.09 per diluted share.
The company highlighted the U.S. launch of its Dexcom G7 15 Day system, FDA clearance for Dexcom Smart Basal, and expanded reimbursement in Québec. Dexcom ended 2025 with $2.00 billion in cash, cash equivalents and marketable securities and reiterated 2026 guidance, including revenue of $5.16–$5.25 billion and non-GAAP operating margin of approximately 22–23%.
Dexcom insider Bridgette P. Heller filed a notice of proposed sale under Rule 144 covering 1,012 shares of common stock, with an aggregate market value of 68826.12. The shares are expected to be sold through Fidelity Brokerage Services on NASDAQ around 02/12/2026.
The securities were originally acquired on 09/29/2021 via restricted stock vesting as compensation. The filing also notes a prior sale on 11/12/2025 of 1,012 shares for gross proceeds of 58766.84. Dexcom had 390,016,272 shares outstanding when this notice was prepared.
Dexcom President and CEO Jacob Steven Leach reported equity compensation activity in the company’s common stock. On January 29, 2026, he received 8,310 shares at $0 upon vesting of previously granted performance-based restricted stock units, reflecting achieved performance goals.
To cover tax withholding on this vesting, 3,058 shares were withheld by Dexcom at $73.36 per share; this withholding is not a sale. After these transactions, Leach directly held 337,051 shares, plus 47,296 shares held indirectly through the Gregg Family Grandchildren's Trust. The direct holdings include 84,537 unvested restricted stock units with various grant and future vesting dates.
EVP and Chief HR Officer Sadie Stern reported routine equity compensation activity. On January 29, 2026, she acquired 7,123 shares of common stock at $0 upon vesting of performance-based restricted stock units granted on March 8, 2023.
The issuer withheld 2,656 shares at $73.36 solely to cover tax obligations related to this vesting, which is not a market sale by Stern. After these transactions, she directly beneficially owned 109,690 shares, including 74,450 unvested restricted stock units scheduled to vest over several dates through March 2028.
DXCM executive vice president and chief financial officer Jereme M. Sylvain reported equity award activity in company common stock. On January 29, 2026, he acquired 7,123 shares at $0 upon vesting of performance-based restricted stock units granted on March 8, 2023 after performance goals were achieved.
On the same date, 2,652 shares were withheld at $73.36 per share to satisfy tax obligations related to this vesting, which the footnotes clarify was not a sale. After these transactions, he directly beneficially owned 123,207 shares, including 83,328 unvested restricted stock units scheduled to vest between March 8, 2026 and March 8, 2028 and 79 shares acquired under the company’s employee stock purchase plan.